These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 15580606

  • 1. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [Abstract] [Full Text] [Related]

  • 2. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [Abstract] [Full Text] [Related]

  • 3. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 4. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

  • 5. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [Abstract] [Full Text] [Related]

  • 6. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, 228 Study Investigators.
    Mov Disord; 2010 May 15; 25(7):858-66. PubMed ID: 20461803
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH, Tang BS, Song CY, Xu Q, Lou MX, Liu ZH, Yu RH, Yan XX, Guo JF.
    Neurosci Lett; 2013 Nov 27; 556():109-12. PubMed ID: 24135335
    [Abstract] [Full Text] [Related]

  • 16. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study.
    Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA.
    Mov Disord; 2005 Jun 27; 20(6):719-25. PubMed ID: 15704188
    [Abstract] [Full Text] [Related]

  • 17. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD.
    Adv Neurol; 1996 Jun 27; 69():3-11. PubMed ID: 8615142
    [No Abstract] [Full Text] [Related]

  • 18. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S, Howard J, Di Rocco A.
    Mov Disord; 2010 Mar 15; 25(4):508-10. PubMed ID: 20014061
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.